| 05/14/2026 4:33 PM | TNF Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 4:19 PM | TNF Pharmaceuticals (1321834) Filer | Form 10-K/A | |
| 04/15/2026 5:29 PM | TNF Pharmaceuticals (1321834) Issuer Silverman Joshua (1524858) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Bernstein Bruce (1665472) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | TNF Pharmaceuticals (1321834) Issuer White Billy Joe (1546805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Glass Mitchell (2023649) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | Friscia Stephen (2028845) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 5:29 PM | TNF Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 4:20 PM | TNF Pharmaceuticals (1321834) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/31/2026 3:30 PM | TNF Pharmaceuticals (1321834) Filer | Form NT 10-K | |
| 03/13/2026 3:30 PM | TNF Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for TNFA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for TNF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/17/2026 11:15 PM | TNF Pharmaceuticals (1321834) Filer | Form EFFECT | |
| 02/11/2026 4:17 PM | TNF Pharmaceuticals (1321834) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 01/30/2026 4:30 PM | TNF Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 01/30/2026 4:31 PM | TNF Pharmaceuticals (1321834) Issuer Voss Chelsea Sierra (2108237) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/23/2026 4:00 PM | TNF Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/09/2025 8:25 AM | TNF Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/01/2025 4:21 PM | TNF Pharmaceuticals (1321834) Filer | Form 424B3 | |
| 11/30/2025 11:15 PM | TNF Pharmaceuticals (1321834) Filer | Form EFFECT | |
| 11/19/2025 4:13 PM | TNF Pharmaceuticals (1321834) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/18/2025 3:29 PM | PharmaCyte Biotech, Inc. (1157075) Filed by TNF Pharmaceuticals (1321834) Subject | Form SCHEDULE 13D/A | |
| 11/18/2025 3:32 PM | PharmaCyte Biotech, Inc. (1157075) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 4:30 PM | TNF Pharmaceuticals (1321834) Issuer White Billy Joe (1546805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 4:30 PM | Glass Mitchell (2023649) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:16 PM | TNF Pharmaceuticals (1321834) Issuer Silverman Joshua (1524858) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:14 PM | TNF Pharmaceuticals (1321834) Issuer RAUCH GARY M (1597530) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:15 PM | Bernstein Bruce (1665472) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 7:16 PM | Friscia Stephen (2028845) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/10/2025 4:26 PM | TNF Pharmaceuticals (1321834) Filer | Form PRE 14A | |
| 10/06/2025 5:51 PM | Bernstein Bruce (1665472) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 10/06/2025 4:29 PM | TNF Pharmaceuticals (1321834) Issuer RAUCH GARY M (1597530) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | TNF Pharmaceuticals (1321834) Issuer White Billy Joe (1546805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | Glass Mitchell (2023649) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | Friscia Stephen (2028845) Reporting TNF Pharmaceuticals (1321834) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:30 PM | TNF Pharmaceuticals (1321834) Issuer Silverman Joshua (1524858) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2025 4:13 PM | TNF Pharmaceuticals (1321834) Filer | Form 8-K/A | |
| 10/03/2025 4:28 PM | TNF Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/03/2025 4:29 PM | TNF Pharmaceuticals (1321834) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 09/26/2025 4:10 PM | TNF Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/10/2025 4:00 PM | TNF Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/05/2025 4:30 PM | TNF Pharmaceuticals (1321834) Filer | Form D Notice of Exempt Offering of Securities | |
One page of the SpaceX S-1 will move this stock overnight (Ad) When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities.
That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown. See the stock the S-1 revealed >> |
| 09/05/2025 4:30 PM | TNF Pharmaceuticals (1321834) Filer | Form 8-K/A | |
| 09/02/2025 8:29 AM | TNF Pharmaceuticals (1321834) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/19/2025 4:15 PM | TNF Pharmaceuticals (1321834) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/14/2025 4:01 PM | TNF Pharmaceuticals (1321834) Filer | Form NT 10-Q | |